Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer

NCT00606879 is registered in ClinicalTrials.gov with SGX Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00606879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00606879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer
Lead sponsor
SGX Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2008
Completion date
June 30, 2009
Enrollment
46 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer